Half-year report · HY
4978.TEDINET S100X33R
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 43
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥974m | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥3.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥547m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥149m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | −¥483m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥45m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥103m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥483m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥103m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥486m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥103m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥104m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥486m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥104m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥9.4bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥688m | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥686m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.7bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥9.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.7bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.8bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.6bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥342m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥131m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥123m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥796m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥412m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥680m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥681m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-5.14 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.11 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.14 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 92.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.8% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment ordinary income | 2025-04-01 → 2025-09-30 | −¥341m |
| Medical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥87m |
| Medical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥87m |
| Medical Businessreportable segment | segment ordinary income | 2025-04-01 → 2025-09-30 | −¥119m |
| Research Support Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥887m |
| Research Support Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥887m |
| Research Support Businessreportable segment | segment ordinary income | 2025-04-01 → 2025-09-30 | −¥23m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥974m |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥974m |
| —segment total | segment ordinary income | 2025-04-01 → 2025-09-30 | −¥142m |
| Reconciling Itemsreconciling | segment ordinary income | 2024-04-01 → 2024-09-30 | −¥378m |
| Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥176m |
| Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥176m |
| Medical Businessreportable segment | segment ordinary income | 2024-04-01 → 2024-09-30 | ¥8m |
| Research Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Research Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Research Support Businessreportable segment | segment ordinary income | 2024-04-01 → 2024-09-30 | ¥267m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| —segment total | segment ordinary income | 2024-04-01 → 2024-09-30 | ¥275m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 470
| Item | Context | Value | Unit |
|---|---|---|---|
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | InterimDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes changes in presentation semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes regarding research and development expenses (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |